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Image: DBD Immunology Laboratories’ collaborators
The DBD Immunology 
Laboratories:  
From Clifton Road to Africa
Diseases 
laboratory
CDC’s Division of Bacterial (DBD) Immunology Laboratories integrate 
, epidemiologic, and statistical approaches 
to enhance the diagnosis and surveillance of agents 
causing respiratory, meningococcal and other priority 
bacterial infections nationally and globally. The labora-
tories work to develop, evaluate, implement and improve 
serologic, immunologic, and molecular biologic methods, 
techniques and strategies. Partnerships are essential to the 
laboratories’ work, which has impact around the globe. For 
example:
Focusing on vaccine clinical trials for priority bacterial 
agents, in collaboration with Atlanta’s Emory University 
Vaccine and Treatment Evaluation Unit, staff are developing 
correlates of protection that are standardized and validated 
for application to the evaluation of new and developing 
vaccines, new diagnostic reagents and methods. Activities 
include work with hybridomas (cells artificially created by 
fusion of activated lymphocytes with neoplastic cells) and 
developing immunizing agents that will be evaluated in ani-
mal models to study immunologic mechanisms in disease 
processes. 
An FDA collaboration focuses on assigning immunologic 
response values to a new standard reference serum used 
in evaluation and licensure of pneumococcal vaccines 
worldwide. It will replace the nearly depleted current refer-
ence serum. The laboratories are also involved in a project 
to develop correlates of protection for evaluation of vac-
cines against pertussis. 
As a World Health Organization (WHO) Collaborating 
Center for Research and Reagents for Human 
Immunoglobulin Subclasses, the laboratories support 
global access to vaccines by providing reference materi-
als, standardized protocols, and hands-on training to 
fellows and guest researchers. The laboratories provide 
consultation to government agencies, domestic and inter-
national collaborators, WHO reference laboratories, vac-
cine manufacturers, academic institutions and the Pan 
American Health Organization. 
The immunology laboratories are a key partner in the 
Gates Foundation funded Meningitis Vaccine Project 
(along with PATH, WHO, the Health Protection Agency 
and the National Institute for Biological Standards and 
Control) that helped bring the new low-cost meningococ-
cal A conjugate vaccine (MenAfriVac™) through clinical 
development to public health availability. DBD’s scientists 
served as one of two international laboratories charged 
with conducting the immunogenicity studies under a 
quality management system for the vaccine’s regulatory 
approval. Chief of the DBD Immunology Laboratories, Dr. 
George Carlone, says, “Our tests on serum from nearly 
5,000 study participants aided development of this new 
vaccine — we are all proud to be a part of this global 
collaboration that has the potential to save thousands 
of young children in sub-Saharan Africa.” DBD has 
worked closely with WHO AFRO and health authorities in 
Burkina Faso over the past few years on data collection 
and evaluation and will assist in the country’s first nation-
al campaign for MenAfriVac™ introduction this fall. 
Beyond its ongoing research, the immunology laborato-
ries operate and maintain a quality management system 
to support vaccine clinical trials and therapeutics evalua-
tion. The laboratories’ strong infrastructure enables CDC 
to provide sound scientific results and stand at the fore-
front of public health efforts to protect the world’s health. 
Implementing New and Underutilized Vaccines (NUVI) Meeting  
Rana Hajjeh, Steve Hadler, Tom Clark and Adam Cohen attended the WHO sponsored Montreux, Switzerland NUVI meeting (June 22-25, 2010) to review the prog-
ress and challenges of implementing introduction of new and underutilized vaccines with immunization partners and representatives from regions with low and mid-
dle income countries. The meeting focused on progress in introducing pneumococcal conjugate (PCV) and rotavirus vaccines, GAVI financing of new vaccines, new 
vaccine implementation issues, adapting cold chain and logistics, and integrated approaches to diarrhea and pneumonia control. At this meeting WHO announced 
prequalification of the new meningococcal A conjugate vaccine (MenAfriVac™) and WHO AFRO presented plans to launch vaccine campaigns in Burkina Faso, 
Mali and Niger this fall. DBD staff met with staff from regional offices and discussed issues related to introduction of pneumococcal and meningococcal vaccines in 
the Meningitis Belt. Rana and Adam participated in a retreat prior to the NUVI meeting during which regional immunization officers discussed their specific vaccine 
introduction issues and relevant updates were presented.  (Please see the DBD Bulletin story “From Clifton Road to Africa” and “Vaccine News – MenAfriVac™” for 
















It has been a hot and busy sum-
mer for all of us at DBD! On the 
U.S. front, many of our staff have 
been providing extensive support 
for the California Department of 
Public Health (CDPH) to control the 
largest pertussis epidemic that the 
state has experienced in the last 55 
years. DBD has provided technical 
support to CDPH and worked with 
communications staff at the division 
and center to mount an impressive 
campaign to increase awareness 
about the disease and educate the 
public about the need for vaccina-
tion. On the global front, our activi-
ties have escalated. Our staff will 
be involved in the first study of its 
kind to assess etiologies of neona-
tal sepsis, a major cause of neona-
tal death in developing countries. 
This will be crucial to develop better 
prevention strategies and improve 
child survival.  Get Smart staff have 
also expanded their reach to sup-
port global efforts to decrease inap-
propriate use of antibiotics. 
In addition, in each issue of this 
bulletin, we choose to highlight one 
of our special activities: this issue 
features our immunology labora-
tories, which have a distinguished 
legacy of significant contributions 
to almost all bacterial vaccines 
currently available. One such vac-
cine that this group helped develop 
is MenAfriVac™, which was just 
prequalified this summer, bring-
ing with it the promise to eliminate 
meningococcal meningitis epidem-
ics, a scourge that has plagued 
the African continent for many 
decades. As we get ready for an 
even busier fall season, I would 
like to thank you all for your tireless 
contributions, and ask to gather our 
energy to assist with the introduc-
tion of meningococcal and pneumo-
coccal vaccines in the many coun-
tries across the world that have 
eagerly waited for them.
    Rana
AWARDS
First Annual NCIRD Honor Awards Ceremony
NCIRD hosted its first annual Honor Awards Ceremony on August 11, 2010. DBD staff were recognized in the following categories: Excellence in Laboratory Research – 
2009 H1N1 NCIRD Inter-divisional Laboratory Serology Team; Excellence in Program Delivery – American Recovery and Reinvestment Act 317 Initiative; Excellence in 
Public Health Protection – 2009 Mumps Outbreak Response Team; Public Health Impact Award – NCIRD 2009 H1N1 Influenza Diagnostic Team; Excellence in Setting 
Long-Range Public Health Goals – Healthy People 2020 Team; Translation of Data into Policy – Group B Streptococcal Disease Prevention Team; Building Bridges – 
Collaborative Success – The CDC Respiratory Disease Outbreak Working Group; and Response to 2009 H1N1 Influenza Pandemic – Response Staff.
HHSInnovates Finalist 
Reducing CDC’s Carbon Footprint through Recycling: The CDC Office of Health and Safety, 
the Laboratory Support Branch, and the labs are contributing to the agency’s goal of reducing solid 
waste output by 50% by the end of FY2013 as mandated by E.O. 13514. Recycling program labs 
are moving CDC towards being a healthier and more environmentally responsible agency – diverting 
nearly 13,772 pounds of solid waste from land fields in 18 months. DBD houses three of the 10 CDC 
labs in the recycling program. In 2009, the program was awarded the CDC “Go Green, Get Healthy” 
Sustainability Award.
Gates Foundation Awards Grant: Aetiology of Neonatal Infections in South Asia (ANISA) Study 
Stephanie Schrag (RDB) will be the Co-PI on a recently funded Gates Foundation study with Samir 
Saha from Dhaka Shishu Hospital, Bangladesh as the PI. Taking place in three countries in South 
Asia (Bangladesh, India and Pakistan) that account for more than a third of all neonatal deaths, the 
study will improve neonatal survival in the region and beyond by describing aetiology of community 
acquired young infant infections, antibiotic sensitivity of bacterial pathogens, and risk factors for 
infection. Joining Stephanie on the study from DBD will be Barry Fields, Jonas Winchell, Maureen 
Diaz, Lesley McGee and Elizabeth Zell. Staff from DVD and the DFBMD laboratory will be involved 
in the study. Slated to start in January 2011 and conclude in 2014, the $11 million study includes 
external partners from Johns Hopkins University, Aga Khan University in Pakistan, the Shivgarh field 
site in India, the International Centre for Diarrhoeal Disease Research in Bangladesh, the University of 
Toronto, and the World Health Organization. 
2010 Statistical Science Awards Ceremony for CDC/ATSDR
Elizabeth Zell was awarded an Honorable Mention in the Theoretical Paper Category for the article she coauthored with Donald  
Rubin from Harvard University, “Dealing with Noncompliance and Missing Outcomes in a Randomized Trial Using Bayesian  
Technology: Prevention of Perinatal Sepsis Clinical Trial, Soweto, South Africa,” published in Statistical Methodology.
Hermes Creative & National Health Information Awards 
The Get Smart campaign video “Snort. Sniffle. Sneeze. No Antibiotics Please!“ won the 2010 Platinum Hermes Creative   
Award. MVPDB’s “Have You Heard (about Meningococcal Disease)?” received the Gold Award. Hermes Creative Awards  
is an international competition for creative professionals involved in the concept, writing and design of traditional materials and  
programs, and emerging technologies. The Get Smart campaign video also won a National Health Information Merit Award.  
The National Health Information Awards program is designed to establish a seal of quality for consumer health information.
Photo courtesy of Greg Knobloch, CDC, Connects 
7/31/2008. Microbiologists Sandy Martin, MT (Left) and 
Sandra Steiner, PhD shown preparing plastics for the CDC 
laboratory-recycling program, were among the six finalists 
for the HHSInnovates award. Both attended the HHSIn-
novates ceremony hosted by HHS Secretary Sebelius in 
Washington, DC. 
 2010  MEETINGS  
    
 Summary  of highlights  from the  
 7th International  Symposium  on  
Pneumococci and Pneumococcal 
 Diseases  available:  www.path. 
 org/vaccineresources/details.   
 php?i=1010.   
    
 Staff from  DBD presented  at the  
 July 2010  International  Conference  
on Emerging Infectious Diseases 
in Atlanta. Rana Hajjeh was the 
co-chair of the scientific program 
committee and Gina Mootrey was 
a member of the committee. 
RDB Branch Chief Cyndy Whitney 
participated in CDC’s “Strategies 
for Improving Global Child 
Survival” Public Health Grand 
Rounds on July 15, 2010. View 
and obtain CE credits:  
www.cdc.gov/about/grand-rounds.
MVPDB presented and par-
ticipated at the 17th International 
Pathogenic Neisseria Conference 
(IPNC 2010) held in Banff, Alberta, 
Canada from September 11-16. 
Visit: www.ipnc2010.com.
MVPDB presented and par-
ticipated in the Ninth International 
Bordetella Symposium in 
Baltimore, MD from September 30 
- October 3, 2010. Visit: www.med-
school/umaryland.edu/bordetella/.
FEATURED PUBLICATIONS
Burton DC, Flannery B, Bennett NM, et al. Socioeconomic and racial/ethnic disparities in bacteremic pneumonia 
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CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using a 23-va-
lent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59:1102-06.
Feikin DR, Jagero G, Aura B, et al. High rate of pneumococcal bacteremia in a prospective cohort of older children 
and adults in an area of high HIV prevalence in rural western Kenya. BMC Infect Dis. 2010;10:186-94.
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the Hib Initiative experience. Vaccine. 2010; Epub ahead of print.
Ojo LR, O’Loughlin RE, Cohen AL, et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine. 
2010; Epub ahead of print.
Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of 
conjugate vaccine use. Pediatrics. 2010;126:e9-17.
Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acel-
lular pertussis vaccine (Tdap) against pertussis. Clin Infect Dis. 2010;51:315-21.
Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: Recommendations of 
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MVPDB Responding To Pertussis In California
The last U.S. pertussis peak was in 2005, when approximately 25,000 cases were reported 
nationally, including roughly 3,000 cases and 8 deaths 
in infants younger than 3 months of age in California. 
On June 17, 2010, the California Department of Public 
Health (CDPH) declared a pertussis epidemic. An increase 
had been first noted in late March among patients admitted 
to a children’s hospital in the state’s Central Valley region. 
By September 28, more than 4,400 pertussis cases had 
been reported and 9 infants, all younger than than 3 
months of age, had died. This is the most cases reported 
in 55 years and the highest incidence in 48 years. MVPDB 
conducted Epi-Aids in the Central Valley region and at the 
CDPH in Richmond. 
To prevent transmission of pertussis to vulnerable infants, 
those too young to be vaccinated, CDPH is raising com-
munity awareness by distributing educational materials 
and providing clinical guidance. Free tetanus, diphtheria, 
and acellular pertussis (Tdap) vaccine doses are being 
made available to birthing hospitals and local health 
departments to support postpartum vaccination of mothers 
and close contacts of newborns. American Recovery and 
Reinvestment Act funding enabled CDPH to implement free 
Tdap postpartum programs for hospitals, offer free Tdap 
vaccine to local health jurisdictions and develop community 
vaccination campaigns.
DBD is providing ongoing technical expertise and support 
to CDPH. DBD educational materials are being widely dis-
tributed, many of which focus on the “cocooning” strategy 
to help protect young infants by improving Tdap vaccina-
tion coverage. Through the division’s collaborative activities 
within NCIRD, CDC’s key messages about pertussis and 
pertussis-containing vaccines are widely used by partners 
and featured in national media coverage. 
Outreach strategies, such as communication with partners 
through the Childhood Immunizations Partner Call, pre-
sentations on a Clinician Outreach Communication Activity 
(COCA) call, and the Immunization Update Webinar for 
clinicians, supported multi-channel message dissemina-
tion. Partners have posted the CDC pertussis link on their 
websites. Updated information and new products, such as 
the NCIRD pertussis flyer and Health-e-Cards, are regularly 
posted on www.cdc.gov/pertussis.
MVPDB staff also continue to work with traditional and 
internet based media with assistance from NCIRD’s Health 
Communication Science Office and CDC’s press office. 
Examples of proactive media include: a Medscape video on 
Tdap recommendations with Stacey Martin viewed by more 
than 30,000 people; a WebMD interview with Tom Clark; 
syndication of the CDC Spanish language pertussis web 
Photo: MVPDB’s Stacey Martin participates in a local 
media interview after the LA ethnic media round table 
feature on the Todobebe.com website; and a text4baby 
phone text message on pertussis prevention to 3,561 CA 
subscribers and more than 54,000 national subscribers. 
National media engagement ranges from the LA Times and 
Sacramento Bee to the New York Times, CNN and ABC 
News. In August, Stacey Martin presented at ethnic media 
round tables hosted by CDPH and CDC in LA and San 
Francisco; and Tom Clark, Tami Skoff, Fátima Coronado, 
Jennifer Liang and CDPH’s Gilberto Chavez were inter-
viewed during a 37-station satellite radio media tour target-
ing CA, SC, OH, MI and upstate NY—all areas showing 
increased pertussis activity. More than 2.4 million impres-
sions (media exposures) can be tracked to these media 
activities.
It is too early to determine if 2010 will be a peak incidence 
year nationally, because even though there have been 
increased pertussis activity and outbreaks in several states, 
some states are reporting less activity than at this time in 
2009. DBD will continue to provide technical assistance to 
health departments and partners in response to pertussis 
activity and outbreaks and work proactively with media and 
health information providers to ensure that appropriate 
pertussis prevention messages reach a wide variety of 
audiences and key informants. 
Edward Jenner Society 
The new Edward Jenner Society 
(aka “The Jenner Society”) will be 
a professional “home” for academic 
vaccinologists. Currently, there 
is no single academic or learned 
society dedicated solely to the 
interests of academic vaccinology 
at the international level: 
edwardjennersociety.org. 
Updated Anthrax Vaccine 
Recommendations 
These recommendations from 
ACIP update the previous recom-
mendations for anthrax vaccine 
adsorbed (AVA). Substantial 
changes to these recommenda-
tions include: 1) reducing the num-
ber of doses required to complete 
the pre-event and preexposure 
primary series from 6 doses to 5 
doses, 2) recommending intramus-
cular rather than subcutaneous 
AVA administration for preexpo-
sure use, 3) recommending AVA 
as a component of post exposure 
prophylaxis in pregnant women 
exposed to aerosolized Bacillus 
anthracis spores, 4) providing guid-
ance regarding preexposure vac-
cination of emergency and other 
responder organizations under the 
direction of an occupational health 
program, and 5) recommending 60 
days of antimicrobial prophylaxis 
in conjunction with 3 doses of AVA 
for optimal protection of previously 
unvaccinated persons after expo-
sure to aerosolized B. anthracis 
spores. MMWR 2010;59(RR-06); 
1-30. 
MenAfriVac™
In the worst epidemic years, over 
200,000 cases of meningococcal 
meningitis can occur in the African 
meningitis belt. A new life sav-
ing meningococcal A conjugate 
vaccine (MenAfriVac™) is being 
made available in Africa for the 
first time since its licensure in early 
2010. Priced at just US$ 0.40 per 
dose, MenAfriVac™ is expected 
to prevent 123,000 deaths over 
the next ten years across the 
meningitis belt. Immunizations are 
already underway in Burkina Faso, 
Mali, and Niger.  Through 2011, 
it is expected that over 30 million 
people will be vaccinated with the 
breakthrough vaccine.  Ultimately, 
over 250 million people will receive 
the vaccine. 
Vaccine News
Photo: MVPDB’s Fabien Diomandé and Ryan Novak walk 
railroad tracks in rural Burkina Faso in sub-Saharan Africa  
to reach a local vaccination site and deliver the new life 









“Get Smart” Campaign Goes Global
Antimicrobial resistance has been called one of the world’s most pressing public 
health problems  – in part because it knows no 
borders. Travel and trade can transport resistant 
bacteria globally. Deaths from acute respiratory 
infections, diarrheal diseases, measles, AIDS, 
malaria and tuberculosis account for more than 
85% of the mortality from infection worldwide and 
development of resistance to antimicrobials is a 
threat for treating almost all of these diseases. 
Staff in the Respiratory Diseases Branch (RDB) 
collaborate with policymakers, scientists and 
communicators around the world to develop and 
implement specific interventions that support the 
right way to use antibiotics for upper respiratory 
infections to cut down on antibiotic use that can 
lead to resistance. 
In Damanhour, Egypt, Lauri Hicks, Medical 
Director for the Get Smart: Know When Antibiotics 
Work campaign, and Dr. Adel Mansour with the 
International Emerging Infections Program (IEIP), 
are working with local health officials on an 
antibiotic prescribing and usage study initiated by 
the U.S. Naval Medical Research Unit (NAMRU). 
The USAID funded project involves local health 
care providers, pharmacists and patients. Get 
Smart campaign experience will be used to 
guide development and testing of antibiotic use 
educational materials appropriate for Egypt. 
Study investigators hope to find out if the 
campaign, which has successfully contributed to 
reducing inappropriate antibiotic use in the U.S., 
can help other nations achieve similar results.
The Get Smart campaign focuses on educating 
health care providers and the public that 
antibiotics should not be prescribed for most 
upper respiratory infections, like colds and most 
sore throats, which are caused by viruses. The 
campaign has been credited with contributing to 
a 20% decline in prescribing for these conditions 
in the U.S.
About the same time Dr. Hicks was meeting with 
colleagues in Egypt, EIS Officer George Nelson 
(RDB) joined a 100-year-old pharmacist in the 
living quarters of his storefront pharmacy halfway 
around the world in Santa Rosa, Guatemala. 
Against a backdrop of medicine bottles and 
posters, the pharmacist described the problems 
with antibiotic use in his community and talked 
about customers who asked him to provide 
antibiotics even though they had no prescription. 
Unpublished data show that in Guatemala, one 
quarter of patients hospitalized for respiratory 
disease report having taken an antibiotic for their 
illness, and most say they get the drugs from a 
health facility or pharmacy. The Ministry of Public 
Health and Social Assistance in Guatemala has 
a strong interest in ensuring antibiotic use and 
is partnering with CDC to conduct a study on 
antibiotic prescribing and dispensing in select 
areas of Guatemala.
Photo: Courtesy of ECDC. “Take care of your 
health – Do not abuse antibiotics” Educational 
Billboard in Malta, during 2009 EU Antibiotic 
Awareness Campaign coordinated by ECDC 
Photo: NAMRU/IEIP staff in Cairo, Egypt. Left 
to right: Kinnery Patel, Maha Talaat, Lauri 
Hicks (CDC Medical Director for Get Smart), 
Sharon Daves, and Erica Dueger
In the fall of 2009, when President Obama signed 
the U.S.–EU Joint Declaration and Annexes 
establishing a transatlantic task force on urgent 
antimicrobial resistance issues, CDC’s Get 
Smart campaign was busy collaborating with the 
European Centre for Disease Prevention and 
Control (ECDC) to plan the first joint transatlantic 
appropriate antibiotic use observance on 
November 18, 2010. For this observance, more 
than 30 countries in the European Union will 
promote appropriate use of antibiotics in hospitals 
and conduct public education activities. In the 
U.S., the Get Smart campaign will support a 
full week of community awareness activities in 
collaboration with its national public and private 
partners.
In addition to the collaborations in Egypt, 
Guatemala, and with ECDC, Lauri Hicks was 
invited by the governments of France, the Czech 
Republic and Canada to share her expertise in 
implementing campaigns for appropriate antibiotic 
use. Antimicrobial use and resistance were a 
featured discussion topic during the CDC-hosted 
International Conference on Emerging Infectious 
Diseases (ICEID) in Atlanta July 11-14. 
To learn more about CDC work in antimicrobial 
resistance and Get Smart About Antibiotics Week 
2010, visit www.cdc.gov/getsmart.
New conjunctivitis website launched June 2010 at www.cdc.gov/conjunctivitis 
New pertussis website launched August 2010 at www.cdc.gov/pertussis
Web features posted recently to CDC’s homepage: GBS, pertussis, conjunctivitis, meningitis
DBD-specific expert video commentaries on Medscape include:
•	 Pertussis – Recognition and Treatment (Tom Clark)
•	 Meningococcal Disease – Prevention, Diagnosis, and Management (Henry Wu)
•	 Pneumococcal Disease in Children – New Immunization Recommendations (Matt Moore)
•	 With Pertussis on the Rise, Who Needs a Tdap Vaccination? (Stacey Martin)
View commentaries at medscape.com/partners/cdc/public/cdc-commentary.  Watch a video about appropriate 
antibiotic use communication tips with Lauri Hicks to be released on November 8th and one about new Group B 
Strep guidelines later in the year.
World Pneumonia Photo Exhibition at CDC starting November 8th 
The second annual World Pneumonia Day is November 12th. The premiere showing of the Photoshare World 
Pneumonia Photo Exhibition was held September 20th at the New York Times Center during the United Nations 
Summit on the Millennium Development Goals. The exhibition is a collaboration between Photoshare and 
the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, in 
partnership with the Global Coalition against Child Pneumonia with sponsorship provided by Nikon. The personal 
images and stories captured in the exhibition come from every corner of the world. NCIRD, along with other CDC 
programs, will host the exhibition at the CDC Public Health Library and Information Center during November. An 
opening reception will take place at noon on November 8th.
Epi-AIDS & 
Investigations
Legionellosis outbreak associated with an Air 
National Guard Base, Michigan – Aug 2010
Statewide epidemic of pertussis - Vaccine program 
evaluation, California – July 2010
Legionnaires’ disease associated with travel to a
hotel, Mississippi – July 2010
Community outbreak of pertussis in the Central 
Valley of California – May 2010
Welcome New EIS Officers
RDB: Tarayn Fairlie and Katherine Fleming-Dutra
MVPDB: Sara Tartof and Andrew Terranella
